ProQR Therapeutics N.V.(PRQR)Earnings, Financials & Key Ratios
PRQR•NASDAQ
Price updated Jun 11, 2026
AboutProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Show more
- Revenue$15M-19.2%
- EBITDA-$40M-42.8%
- Net Income-$41M-45.9%
- EPS (Diluted)-0.38-11.8%
- Gross Margin83.01%-17.0%
- EBITDA Margin-258.92%-76.6%
- Operating Margin-275.91%-71.2%
- Net Margin-265.21%-80.6%
- ROE-58.76%-42.1%
- Debt/Equity0.28+45.8%
- Interest Coverage-48.66-94.9%
PRQR Key Insights
ProQR Therapeutics N.V. (PRQR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 71.5%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 29.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PRQR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRQR Price & Volume
ProQR Therapeutics N.V. (PRQR) stock price & volume — 10-year historical chart
Loading chart...
PRQR Growth Metrics
ProQR Therapeutics N.V. (PRQR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.97%
5 Years71.53%
3 Years61.99%
TTM-29.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-51.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-27.11%
Return on Capital
10 Years-43.64%
5 Years-33.6%
3 Years-29.78%
Last Year-40.27%
PRQR Recent Earnings
ProQR Therapeutics N.V. (PRQR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 12, 2026EPS
$0.15
Est $0.15
+0.0%
Revenue
$2M
Est $5M
-54.7%
Q2 2026
Mar 12, 2026EPS
$0.09
Est $0.08
-12.5%
Revenue
$6M
Est $7M
-16.4%
Q4 2025
Nov 6, 2025EPS
$0.12
Est $0.10
-20.0%
Revenue
$3M
Est $6M
-44.2%
Q3 2025
Aug 7, 2025EPS
$0.14
Est $0.08
-75.0%
Revenue
$4M
Est $5M
-18.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.15vs $0.15+0.0% | $2Mvs $5M-54.7% |
| Q2 2026 | Mar 12, 2026 | $0.09vs $0.08-12.5% | $6Mvs $7M-16.4% |
| Q4 2025 | Nov 6, 2025 | $0.12vs $0.10-20.0% | $3Mvs $6M-44.2% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.08-75.0% | $4Mvs $5M-18.2% |
Based on last 12 quarters of dataView full earnings history →
PRQR Peer Comparison
ProQR Therapeutics N.V. (PRQR) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 238.89M | 2.44 | -1.36 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CRSP | 4.84B | 50.23 | -7.76 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ARWR | 10.48B | 74.41 | -6099.18 | 232.58% | -48.38% | -55.09% | 0.73 | |
 QURE | 1.68B | 26.82 | -7.75 | -40.64% | -11.54% | -145.81% | 2.70 | |
 RCKT | 290.45M | 2.66 | -1.32 | -70.79% | 0.09 | |||
 REPL | 711.78M | 8.62 | -2.81 | -102.69% | 0.18 |
Compare PRQR vs Peers
ProQR Therapeutics N.V. (PRQR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRQR Income Statement
ProQR Therapeutics N.V. (PRQR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | -1.53M | 4.94M | 1.93M | 1.03M | 1.33M | 3.59M | 6.51M | 18.91M | 15.28M | 13.44M |
Revenue Growth % | -167% | 423.15% | -60.88% | -46.77% | 29.74% | 169.21% | 81.25% | 190.22% | -19.18% | -29.15% |
Cost of Goods Sold | 1M | 983.51K | 116.82M | 0 | 0 | 0 | 0 | 0 | 2.6M | 1.38M |
COGS % of Revenue | -65.49% | 19.91% | 6043.61% | - | - | - | - | - | 16.99% | - |
Gross Profit | -2.53M▲ 0% | 3.96M▲ 256.4% | -114.89M▼ 3003.1% | 1.03M▲ 100.9% | 1.33M▲ 29.7% | 3.59M▲ 169.2% | 6.51M▲ 81.2% | 18.91M▲ 190.2% | 12.68M▼ 32.9% | 12.06M▲ 0% |
Gross Margin % | 165.49% | 80.09% | -5943.61% | 100% | 100% | 100% | 100% | 100% | 83.01% | 89.75% |
Gross Profit Growth % | -352.93% | 256.4% | -3003.1% | 100.9% | 29.74% | 169.21% | 81.25% | 190.22% | -32.92% | - |
Operating Expenses | 41.99M | 42.05M | 59.38M | 43.4M | 58.55M | 68.75M | 38.37M | 49.38M | 54.84M | 58.51M |
OpEx % of Revenue | -2746.44% | 851.12% | 3071.81% | 4217.4% | 4385.39% | 1912.99% | 589.09% | 261.18% | 358.92% | - |
Selling, General & Admin | 10.84M | 12.54M | 12.89M | 13.69M | 17.37M | 18.65M | 16.24M | 13.66M | 14.12M | 14.33M |
SG&A % of Revenue | -708.96% | 253.79% | 666.68% | 1329.93% | 1300.97% | 518.95% | 249.25% | 72.26% | 92.41% | - |
Research & Development | 31.15M | 29.51M | 46.49M | 38.13M | 42.22M | 50.87M | 25.15M | 36.36M | 40.72M | 44.34M |
R&D % of Revenue | -2037.48% | 597.33% | 2405.12% | 3706.03% | 3162.55% | 1415.33% | 386.06% | 192.31% | 266.51% | - |
Other Operating Expenses | 1.5M | 5.76M | 1.93M | -8.42M | -1.04M | -765K | -3.01M | -640K | 0 | -158K |
Operating Income | -40.5M▲ 0% | -36.29M▲ 10.4% | -57.45M▼ 58.3% | -42.37M▲ 26.2% | -57.21M▼ 35.0% | -65.16M▼ 13.9% | -31.86M▲ 51.1% | -30.47M▲ 4.4% | -42.15M▼ 38.3% | -46.45M▲ 0% |
Operating Margin % | 2648.66% | -734.53% | -2971.81% | -4117.4% | -4285.39% | -1812.99% | -489.09% | -161.18% | -275.91% | -345.52% |
Operating Income Growth % | -2.34% | 10.38% | -58.28% | 26.25% | -35.03% | -13.89% | 51.11% | 4.35% | -38.34% | - |
EBITDA | -39.5M | -35.31M | -55.4M | -40.01M | -54.88M | -62.64M | -29.35M | -27.71M | -39.56M | -43.72M |
EBITDA Margin % | 2583.17% | -714.62% | -2865.96% | -3888.54% | -4110.94% | -1742.85% | -450.51% | -146.58% | -258.92% | -325.25% |
EBITDA Growth % | -3.15% | 10.6% | -56.9% | 27.77% | -37.16% | -14.13% | 53.15% | 5.57% | -42.75% | -43.52% |
D&A (Non-Cash Add-back) | 1M | 983.51K | 2.05M | 2.35M | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M | 2.72M |
EBIT | 0 | -36.27M | -172.35M | -50.79M | -57.28M | -58.98M | -26.61M | -26.88M | -42.15M | -46.17M |
Net Interest Income | -3.77M | -1.6M | -681K | -1.73M | -3.4M | -5.02M | 1.39M | 2.17M | 1.37M | 525.37K |
Interest Income | -3.17M | -792K | 402K | 313K | 5K | 106K | 2.59M | 3.25M | 2.24M | 525.37K |
Interest Expense | 596K | 810K | 1.08M | 2.04M | 3.4M | 5.13M | 1.2M | 1.08M | 866.4K | 0 |
Other Income/Expense | 850.31K | -792K | 117.65M | -4.12M | -3.47M | 1.05M | 4.05M | 2.51M | 1.65M | 840.44K |
Pretax Income | -43.67M▲ 0% | -37.09M▲ 15.1% | -56.61M▼ 52.7% | -46.49M▲ 17.9% | -60.68M▼ 30.5% | -64.11M▼ 5.6% | -27.81M▲ 56.6% | -27.96M▼ 0.5% | -40.5M▼ 44.9% | -45.61M▲ 0% |
Pretax Margin % | 2856.31% | -750.56% | -2928.82% | -4517.98% | -4545.47% | -1783.75% | -426.97% | -147.9% | -265.09% | -339.26% |
Income Tax | 2K | 1K | 132K | 124K | 117K | 96K | -78K | -197K | 18.25K | 18.99K |
Effective Tax Rate % | -0% | -0% | -0.23% | -0.27% | -0.19% | -0.15% | 0.28% | 0.7% | -0.05% | -0.04% |
Net Income | -43.64M▲ 0% | -36.89M▲ 15.5% | -56.75M▼ 53.8% | -46.56M▲ 17.9% | -60.74M▼ 30.4% | -64.42M▼ 6.1% | -28.12M▲ 56.4% | -27.76M▲ 1.3% | -40.52M▼ 45.9% | -45.62M▲ 0% |
Net Margin % | 2853.96% | -746.69% | -2935.64% | -4525.27% | -4549.81% | -1792.54% | -431.67% | -146.86% | -265.21% | -339.41% |
Net Income Growth % | -11.59% | 15.45% | -53.81% | 17.94% | -30.44% | -6.07% | 56.35% | 1.27% | -45.95% | -51.15% |
Net Income (Continuing) | -43.64M | -36.89M | -56.75M | -46.61M | -60.8M | -64.2M | -27.73M | -27.76M | -40.52M | -45.62M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -38K | -230K | -556.76K | -666.83K | -604K | -384K | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.72▲ 0% | -1.08▲ 37.2% | -1.38▼ 27.8% | -0.93▲ 32.6% | -0.96▼ 3.2% | -0.91▲ 5.2% | -0.35▲ 61.5% | -0.34▲ 2.9% | -0.38▼ 11.8% | -0.43▲ 0% |
EPS Growth % | -2.99% | 37.21% | -27.78% | 32.61% | -3.23% | 5.21% | 61.54% | 2.86% | -11.76% | -27.11% |
EPS (Basic) | -1.72 | -1.08 | -1.38 | -0.93 | -0.96 | -0.91 | -0.35 | -0.34 | -0.38 | - |
Diluted Shares Outstanding | 25.37M | 34.05M | 41.04M | 50.06M | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M | 105.36M |
Basic Shares Outstanding | 25.37M | 34.05M | 41.04M | 50.06M | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M | 105.36M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PRQR Balance Sheet
ProQR Therapeutics N.V. (PRQR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 50.56M | 108.37M | 128.71M | 97.91M | 191.48M | 154.46M | 133.65M | 153.84M | 100.08M | 87.07M |
Cash & Short-Term Investments | 48.1M | 105.58M | 125.66M | 92.79M | 187.52M | 94.78M | 131.37M | 149.41M | 92.37M | 81.17M |
Cash Only | 48.1M | 105.58M | 125.66M | 92.79M | 187.52M | 94.78M | 131.37M | 149.41M | 92.37M | 81.17M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 1.24M | 1.34M | 978.84K | 0 | 56.25M | 1.4M | 0 | 5.08M | 2.72M |
Days Sales Outstanding | - | 91.82 | 252.23 | 347.21 | - | 5.71K | 78.49 | - | 121.45 | 52.97 |
Inventory | 73K | 899K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 26.61 | 333.64 | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | -2.79M | 0 | 0 | 823K | 982K | 0 | 2.03M | 0 | 0 |
Total Non-Current Assets | 2.54M | 1.86M | 3.22M | 22.89M | 18.1M | 16.86M | 18.67M | 14.11M | 12.62M | 12.06M |
Property, Plant & Equipment | 2.5M | 1.86M | 2.74M | 22.76M | 17.47M | 16.24M | 18.67M | 14.11M | 12.62M | 12.06M |
Fixed Asset Turnover | -0.61x | 2.65x | 0.71x | 0.05x | 0.08x | 0.22x | 0.35x | 1.34x | 1.21x | 1.06x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 481.55K | 130.92K | 629K | 621K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Total Assets | 53.1M▲ 0% | 110.23M▲ 107.6% | 131.93M▲ 19.7% | 120.8M▼ 8.4% | 209.58M▲ 73.5% | 171.32M▼ 18.3% | 152.31M▼ 11.1% | 167.96M▲ 10.3% | 112.71M▼ 32.9% | 99.14M▲ 0% |
Asset Turnover | -0.03x | 0.04x | 0.01x | 0.01x | 0.01x | 0.02x | 0.04x | 0.11x | 0.14x | 0.11x |
Asset Growth % | -18.98% | 107.58% | 19.69% | -8.44% | 73.49% | -18.25% | -11.1% | 10.27% | -32.9% | -39.51% |
Total Current Liabilities | 8.49M | 8.16M | 12.34M | 12.6M | 27.6M | 20.99M | 37.78M | 38.9M | 32.43M | 35.09M |
Accounts Payable | 546K | 135K | 499.51K | 270.4K | 191K | 392K | 1.7M | 16K | 297.87K | 189.2K |
Days Payables Outstanding | 199.03 | 50.1 | 1.56 | - | - | - | - | - | 41.88 | 137.41 |
Short-Term Debt | 1.96M | 0 | 955.25K | 2.93M | 4.77M | 2.5M | 1.78M | 4.58M | 4.44M | 4.62M |
Deferred Revenue (Current) | 347K | 545K | 798.1K | 856.49K | 0 | 0 | 22.72M | 0 | 17.54M | 37.17M |
Other Current Liabilities | 4.62M | 7.48M | 10.01M | 8.54M | 19.87M | 15.59M | 11.58M | 31.26M | 10.14M | 10.66M |
Current Ratio | 5.95x | 13.28x | 10.43x | 7.77x | 6.94x | 7.36x | 3.54x | 3.95x | 3.09x | 2.48x |
Quick Ratio | 5.94x | 13.17x | 10.43x | 7.77x | 6.94x | 7.36x | 3.54x | 3.95x | 3.09x | 2.48x |
Cash Conversion Cycle | - | 375.36 | - | - | - | - | - | - | - | -84.44 |
Total Non-Current Liabilities | 5.28M | 9.39M | 14.27M | 39.01M | 68.75M | 83.65M | 68.81M | 40.5M | 30.93M | 26.41M |
Long-Term Debt | 5.28M | 9.39M | 14.27M | 19.81M | 39.32M | 4.27M | 4.74M | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 19.2M | 14.75M | 13.81M | 15.28M | 11.07M | 9.54M | 39.12M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 14.69M | 65.57M | 0 | 29.43M | 0 | 0 |
Total Liabilities | 13.78M | 17.55M | 26.61M | 51.61M | 96.35M | 104.64M | 106.59M | 79.4M | 63.36M | 61.5M |
Total Debt | 7.24M | 9.39M | 15.22M | 41.94M | 60.37M | 21.97M | 21.8M | 17.22M | 13.99M | 13.7M |
Net Debt | -40.85M | -96.19M | -110.44M | -50.85M | -127.15M | -72.8M | -109.57M | -132.19M | -78.39M | -67.47M |
Debt / Equity | 0.18x | 0.10x | 0.14x | 0.61x | 0.53x | 0.33x | 0.48x | 0.19x | 0.28x | 0.36x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.31x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.54x |
Interest Coverage | -67.95x | -44.78x | -159.14x | -24.90x | -16.82x | -11.50x | -22.12x | -24.96x | -48.66x | - |
Total Equity | 39.33M▲ 0% | 92.69M▲ 135.7% | 105.33M▲ 13.6% | 69.19M▼ 34.3% | 113.23M▲ 63.7% | 66.68M▼ 41.1% | 45.72M▼ 31.4% | 88.56M▲ 93.7% | 49.35M▼ 44.3% | 37.64M▲ 0% |
Equity Growth % | -25.99% | 135.69% | 13.64% | -34.31% | 63.66% | -41.11% | -31.43% | 93.69% | -44.27% | 132.2% |
Book Value per Share | 1.55 | 2.72 | 2.57 | 1.38 | 1.76 | 0.93 | 0.56 | 1.08 | 0.47 | 0.36 |
Total Shareholders' Equity | 39.36M | 92.92M | 105.88M | 69.85M | 113.83M | 67.06M | 45.72M | 88.56M | 49.35M | 37.64M |
Common Stock | 1.46M | 1.73M | 2.42M | 2.65M | 3M | 3.37M | 3.72M | 4.31M | 4.31M | 4.31M |
Retained Earnings | -119.37M | -155.44M | -237.68M | -315.37M | -317.77M | -379.11M | -442.8M | -427.16M | -467.31M | -479.39M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 136K | 108K | 18.75M | 29.26M | 30.3M | 30.26M | 28.69M | 27.6M | 28.68M | 28.33M |
Minority Interest | -38K | -230K | -556.76K | -666.83K | -604K | -384K | 0 | 0 | 0 | 0 |
PRQR Cash Flow Statement
ProQR Therapeutics N.V. (PRQR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -34.95M | -30.68M | -43.97M | -47.06M | -26.01M | -68.51M | 21.55M | -36.39M | -50.71M | -48.04M |
Operating CF Margin % | 2285.87% | -620.97% | -2274.7% | -4573.38% | -1948.46% | -1906.18% | 330.8% | -192.5% | -331.89% | - |
Operating CF Growth % | -2.13% | 12.21% | -43.31% | -7.03% | 44.73% | -163.37% | 131.45% | -268.89% | -39.33% | -210.09% |
Net Income | -43.52M | -37.09M | -56.75M | -46.61M | -60.8M | -64.2M | -27.73M | -27.76M | -40.52M | -45.62M |
Depreciation & Amortization | 1.06M | 992K | 2.05M | 2.35M | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M | 2.72M |
Stock-Based Compensation | 4.02M | 3.22M | 9.11M | 7.84M | 6.22M | 2.87M | 3.11M | 2.54M | 0 | 2.03M |
Deferred Taxes | 145K | 102K | 132K | 124K | 117K | 96K | -78K | -197K | 0 | 18K |
Other Non-Cash Items | 3.17M | 792K | -210K | -5.29M | 1.11M | -4.8M | -5.21M | -474K | 3.94M | 3.3M |
Working Capital Changes | 164K | 1.29M | 1.69M | -5.47M | 25.01M | -4.99M | 48.96M | -13.26M | -16.73M | -10.48M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -121K | -312K | -580K | -924K | -425K | -702K | 4.28M | -4.07M | -979.74K | -955.79K |
Capital Expenditures | -121K | -312K | -580K | -924K | -484K | -708K | -1.37M | -1.42M | -979.74K | -955.79K |
CapEx % of Revenue | -7.91% | 6.31% | 30.01% | 89.8% | 36.25% | 19.7% | 21.05% | 7.5% | 6.41% | 7.11% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 59K | 6K | 5.65M | -2.65M | 0 | 0 |
Cash from Financing | 26.64M | 88.65M | 50.2M | 14.5M | 136.83M | -30.89M | -2.27M | 70.28M | -1.76M | -1.63M |
Debt Issued (Net) | 951K | 1.4M | 1.46M | 13.77M | 26.84M | -45.05M | -2.63M | -1.58M | -1.91M | -1.64M |
Equity Issued (Net) | 25.68M | 84.19M | 48.55M | 0 | 108.48M | 14.12M | 0 | 71.64M | 66.28K | 1.71K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 4K | 870K | 193K | 735K | 1.52M | 34K | 354K | 223K | 75.19K | 5.85K |
Net Change in Cash | -11.1M▲ 0% | 57.48M▲ 617.8% | 6.37M▼ 88.9% | -36.11M▼ 666.9% | 111.69M▲ 409.3% | -92.75M▼ 183.0% | 24.15M▲ 126.0% | 30.48M▲ 26.2% | -39.3M▼ 228.9% | -53.17M▲ 0% |
Free Cash Flow | -35.07M▲ 0% | -30.99M▲ 11.6% | -44.55M▼ 43.7% | -47.98M▼ 7.7% | -26.5M▲ 44.8% | -69.22M▼ 161.2% | 20.18M▲ 129.2% | -37.81M▼ 287.4% | -51.69M▼ 36.7% | -48.99M▲ 0% |
FCF Margin % | 2293.79% | -627.28% | -2304.71% | -4663.17% | -1984.72% | -1925.88% | 309.75% | -200.01% | -338.31% | -364.47% |
FCF Growth % | 4.59% | 11.63% | -43.74% | -7.71% | 44.78% | -161.23% | 129.15% | -287.4% | -36.7% | -29.04% |
FCF per Share | -1.38 | -0.91 | -1.09 | -0.96 | -0.41 | -0.97 | 0.25 | -0.46 | -0.49 | -0.47 |
FCF Conversion (FCF/Net Income) | 0.80x | 0.83x | 0.77x | 1.01x | 0.43x | 1.06x | -0.77x | 1.31x | 1.25x | 1.07x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRQR Key Ratios
ProQR Therapeutics N.V. (PRQR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -94.39% | -55.9% | -57.32% | -53.37% | -66.6% | -71.62% | -50.03% | -41.35% | -58.76% | -86.47% |
| Return on Invested Capital (ROIC) | - | - | - | -480.74% | -1945.08% | - | - | - | - | 108.76% |
| Gross Margin | 165.49% | 80.09% | -5943.61% | 100% | 100% | 100% | 100% | 100% | 83.01% | 89.75% |
| Net Margin | 2853.96% | -746.69% | -2935.64% | -4525.27% | -4549.81% | -1792.54% | -431.67% | -146.86% | -265.21% | -339.41% |
| Debt / Equity | 0.18x | 0.10x | 0.14x | 0.61x | 0.53x | 0.33x | 0.48x | 0.19x | 0.28x | 0.36x |
| Interest Coverage | -67.95x | -44.78x | -159.14x | -24.90x | -16.82x | -11.50x | -22.12x | -24.96x | -48.66x | - |
| FCF Conversion | 0.80x | 0.83x | 0.77x | 1.01x | 0.43x | 1.06x | -0.77x | 1.31x | 1.25x | 1.07x |
| Revenue Growth | -167% | 423.15% | -60.88% | -46.77% | 29.74% | 169.21% | 81.25% | 190.22% | -19.18% | -29.15% |
Related:PRQR Dividend History·PRQR Revenue History·PRQR Price History·PRQR P/E History·PRQR Financial Ratios·PRQR Institutional Holders
PRQR Frequently Asked Questions
ProQR Therapeutics N.V. (PRQR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ProQR Therapeutics N.V. (PRQR) reported $13.4M in revenue for fiscal year 2025.
ProQR Therapeutics N.V. (PRQR) saw revenue decline by 19.2% over the past year.
ProQR Therapeutics N.V. (PRQR) reported a net loss of $45.6M for fiscal year 2025.
Dividend & Returns
ProQR Therapeutics N.V. (PRQR) has a return on equity (ROE) of -58.8%. Negative ROE indicates the company is unprofitable.
ProQR Therapeutics N.V. (PRQR) had negative free cash flow of $49.0M in fiscal year 2025, likely due to heavy capital investments.